Annovis Bio, Inc. (ANVS) NYSE
1.86
+0.04(+2.20%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
1.86
+0.04(+2.20%)
Currency In USD
Address
1055 Westlakes Drive
Malvern, PA 19312
United States of America (the)
Phone
610 727 3913
Website
Sector
Healthcare
Industry
Biotechnology
Employees
8
First IPO Date
January 29, 2020
| Name | Title | Pay | Year Born |
| Maria L. Maccecchini | Founder, Acting CFO, CEO, President & Executive Director | 808,000 | 1951 |
| Cheng Fang | Senior Vice President of Research & Development | 0 | N/A |
| Blake Jensen | Head of Quality | 0 | N/A |
| Eve Damiano | Senior Vice President of Regulatory Operations | 0 | N/A |
| Hilda Maibach | Senior Vice President of Statistics | 0 | N/A |
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.